Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar)

NCT00876824 is registered in ClinicalTrials.gov with Bharat Serums and Vaccines Limited as lead sponsor.

NCT NCT00876824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00876824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar)
Lead sponsor
Bharat Serums and Vaccines Limited
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2009
Completion date
January 31, 2011
Enrollment
500 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

leishmaniasis, visceral